Talicia is listed as a First-line H. Pylori Treatment Option by the American College of Gastroenterology (ACG)1
Empiric use supported by the latest ACG Clinical Guideline—antibiotic susceptibility testing not required1
START SIMPLE, START STRONG with Talicia as your FIRST CHOICE
Talicia was specifically designed to simplify H. pylori treatment for a broad range of patients
| Talicia1-3 | Clarithromycin- PPI Triple1,4 | Bismuth Quadruple1 | Vonoprazan Dual1,4,5 | Vonoprazan Triple1,4,5 | |
|---|---|---|---|---|---|
| All-in-one capsule formulation |  |  | | | |
| Minimal concerns for resistance* | | | | | |
| Clarithromycin-free formulation | | | | | |
| Treatment warranty program | | | | | |
*As evidenced by ACG Clinical Guideline empiric use.
References: 1. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;112(9):1730-1753. 2. Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020;172(12):795-802. 3. TALICIA Prescribing Information. RedHill Biopharma Inc.; 2024. 4. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608-619. 5. VOQUEZNA Triple Pak and VOQUEZNA Dual Pak Prescribing Information. Phathom Pharmaceuticals; 2024.